CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Dec. 2, 2019—Qiagen and DiaSorin announced FDA approval of the Liaison QuantiFeron-TB Plus Test, developed by Qiagen and DiaSorin, and the U.S. launch of an automated workflow for QFT-Plus on Liaison platforms. The workflow pairs standard QuantiFeron-TB Gold Plus blood collection tubes with the Liaison QFT-Plus detection assay.
“QFT-Plus users are gaining access to the Liaison’s powerful, highly flexible automation for all throughput segments, as well as to Liaison’s broad menu of more than 100 tests,” Thierry Bernard, interim CEO of Qiagen and senior vice president, head of the molecular diagnostics business, said in a company press release.
Pages: 1 2